• Dr. Gunda Georg

    A new drug for pancreatic cancer takes the stage for clinical trials

    What does it take to get to that moment in a clinic when a doctor gives a patient a compound never before used in modern medicine? The story of Minnelide, an investigational drug for pancreatic cancer patients now in a Phase IA clinical trial at the University of Minnesota, illustrates just how complex and exhilarating that journey can be.

    Read more

  • Gunda George

    Gamechanger: Gunda Georg

    Gunda Georg is an esteemed researcher and professor who has made a tremendous impact in the field of synthetic medicinal chemistry.

    Read more

  • Abstract image

    Gunda Georg Inducted into the Academy for Excellence in Health Research

    The Academy for Excellence in Health Research is the highest recognition of excellence in research by Academic Health Center faculty

    Read more

  • Gunda Georg, and Vadim JGurvich

    Welcome to the Institute for Therapeutics Discovery & Development

    ITDD creates opportunities for drug discovery and early pre-clinical drug development through collaborations between various schools, colleges and research centers, as well as industrial throughout Minnesota and nationwide.

    Learn more about our scientific services

  • pills

    Hormone-Free Birth Control Research Advances

    Researchers will investigate pharmaceutical alternatives to existing hormone-based birth control under a new $8.3M NIH contract.

 The Journal of Medicinal Chemistry

The Journal of Medicinal Chemistry publishes studies that contribute to an understanding of the relationship between molecular structure and biological activity or mode of action.

See journal

News

Dr. Gunda Georg and the ITDD are Featured in Article

Gunda Georg and ITDD are featured in the 

Read more...

Dr. Peter Dosa Receives NIH Award

Dr. Peter Dosa has received a $190,625 NIH award for his project, "A pharmacological screen for inactivating antagonists."

The University of Minnesota Joins National Partnership Aimed at Expanding Biopharmaceutical Workforce and Industry

The University of Minnesota will join a team of academic institutions, private companies, governmental entities and non-profit organizations across the U.S.

Gunda GeorgGunda I. Georg, PhD

Director, Institute for Therapeutics Discovery and Development
Professor and Department Head, Department of Medicinal Chemistry; Robert Vince Endowed Chair; McKnight Presidential Chair

Dr. Georg’s expertise includes synthetic medicinal agents, natural products chemistry, and the development of new synthetic methods. She is the co-inventor of Lusedra® and several other drug candidates, as well as the co-founder of ProQuest Pharmaceuticals, Inc. (now a part of Eisai Pharmaceuticals). The ITDD core directors have extensive academic and industrial drug discovery and development expertise. The group uses advanced research and development techniques, including high through-put screening, structure-based drug design, computer modeling, chem- and bioinformatics methods, and animal models to translate basic biomedical discoveries towards new approaches for prevention, treatment, and cures

Vadim GurvichVadim J. Gurvich, PhD, MBA

Associate Director, Institute for Therapeutics Discovery and Development
Director, Chemical Process Development Core

Michael WaltersMichael A. Walters, PhD

Director, Lead and Probe Discovery Core
Institute for Therapeutics Discovery and Development